Liver cancer is the fourth most common cause of cancer‐related death worldwide, with
hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver …

Background and Aims The survival benefit of sorafenib for patients with hepatocellular
carcinoma (HCC) is unsatisfactory due to the development of adaptive resistance …

Sorafenib is the first and currently the only standard treatment for advanced hepatocellular
carcinoma (HCC). We previously developed a sorafenib derivative SC-43, which exhibits …

Background & Aims Shp2 is an SH2-tyrosine phosphatase acting downstream of receptor
tyrosine kinases (RTKs). Most recent data demonstrated a liver tumor-suppressing role for …

The survival benefit of sorafenib for hepatocellular carcinoma (HCC) patients is
unsatisfactory due to the development of adaptive resistance. Increasing evidence has …

Adaptive resistance to MEK inhibitors (MEKi) typically occurs via induction of genes for
different receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same …

Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma
(HCC). Here, we report that Src homology region 2 (SH2) domain-containing phosphatase 1 …

Purpose Hepatocellular carcinoma (HCC) is among the most lethal human malignancies,
and curative therapy is not an option for most patients. There is growing interest in the …

BACKGROUND & AIMS: Recently, we reported that sorafenib sensitizes hepatocellular
carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of …

The multiple kinase inhibitor dovitinib is currently under clinical investigation for
hepatocellular carcinoma (HCC). Here, we investigated the mechanistic basis for the effects …